Castle Biosciences Announces Publication Of New Study Highlighting Demand For Molecular Testing In Atopic Dermatitis
Study data showed more than half of patients who used targeted systemic therapies modified treatment due to lack of efficacyAmong patients surveyed in the study, 94% of those open to a new systemic therapy expressed
Castle Biosciences published research showing that many atopic dermatitis patients need better testing. The study suggests demand exists for their molecular testing tools to help doctors pick the right treatments.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.